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Abstract
Bypassing estrogen receptor (ER) signaling during development of endocrine resistance remains
the most common cause of disease progression and mortality in breast cancer patients. To date, the
majority of molecular research on ER action in breast cancer has occurred in cell line models
derived from late stage disease. Here we describe patient-derived ER + luminal breast tumor
models for the study of intratumoral hormone and receptor action. Human breast tumor samples
obtained from patients post surgery were immediately transplanted into NOD/SCID or NOD/
SCID/ILIIrg−/− mice under estrogen supplementation. Five transplantable patient-derived ER +
breast cancer xenografts were established, derived from both primary and metastatic cases. These
were assessed for estrogen dependency, steroid receptor expression, cancer stem cell content, and
endocrine therapy response. Gene expression patterns were determined in select tumors ±estrogen
and ±endocrine therapy. Xenografts morphologically resembled the patient tumors of origin, and
expressed similar levels of ER (5–99 %), and progesterone and androgen receptors, over multiple
passages. Four of the tumor xenografts were estrogen dependent, and tamoxifen or estrogen
withdrawal (EWD) treatment abrogated estrogen-dependent growth and/or tumor morphology.
Analysis of the ER transcriptome in select tumors revealed notable differences in ER mechanism
of action, and downstream activated signaling networks, in addition to identifying a small set of
common estrogen-regulated genes. Treatment of a na¨ıve tumor with tamoxifen or EWD showed
similar phenotypic responses, but relatively few similarities in estrogen-dependent transcription,
and affected signaling pathways. Several core estrogen centric genes were shared with traditional
cell line models. However, novel tumor-specific estrogen-regulated potential target genes, such as
cancer/testis antigen 45, were uncovered. These results evoke the importance of mapping both
conserved and tumor-unique ER programs in breast cancers. Furthermore, they underscore the
importance of primary xenografts for improved understanding of ER+ breast cancer heterogeneity
and development of personalized therapies.
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Introduction
Steroid hormone receptors play important prognostic and biological roles in breast cancer.
Despite many advances in our understanding breast malignancies during the last several
decades, estrogen receptor (ER) still remains the single most important prognostic and
predictive factor determining treatment outcomes. Thus, endocrine therapies targeting ER
and estrogen production remain the cornerstone of breast cancer treatment for most patients
[1]. Receptors for progesterone (PR) and androgens (AR) also play significant roles in breast
cancer biology. PR, an estrogen-regulated gene, is often co-expressed with ER,
independently predicts outcome in breast cancer [2], and has been implicated in regulating
stem-like cancer cells [reviewed in 3]. AR is expressed in ~70–80 % of breast cancers [4, 5],
is generally considered to be growth inhibitory in ER+ tumors [6], and potentially mitogenic
in some ER− tumors [7]. In a recent breast cancer classification study, six subgroups with
distinct clinical features could be distinguished by gene clusters centered on ER, AR, and
cell cycle regulators [8]. Thus, dissecting the roles of steroid receptors, especially ER, in
breast cancer biology remains essential for understanding and overcoming treatment
resistance.
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Breast cancers are divided into three main entities that inform treatment decisions: ER+
PR(+/−), HER2 amplified, and triple negative (TN). Molecular subtyping based on gene
expression signatures has further divided breast tumors into multiple groups with distinct
outcomes in anticipation of developing new treatment targets and strategies [9]. Luminal
breast cancers are defined by ER positivity but otherwise represent a diverse group of
tumors in regard to their origin (ductal or lobular), histological features, and expression of
nuclear (PR or AR) and cell surface receptors (HER2). Although luminal tumors have an
overall better prognosis compared to ER–/HER2 amplified and TN tumors, up to 40 %
eventually escape endocrine therapies, recur in a more untreatable state, often many years
later, and still account for the majority of overall breast cancer mortality [10]. ER expression
in luminal tumors can range from 1 to 99 % positive cells; more highly ER+ tumors are
generally slower growing, low-mid grade, and have a more “pure” luminal phenotype.
Lower ER scores usually correlate with higher proliferation indices, higher grade, and
sometimes “mixed” luminal/basal features [11]. Nonetheless, even patients with 1 % of
strongly ER+ tumor cells clinically benefit from endocrine therapies [12]. Thus, the
determinants that define responsiveness lie beyond ER levels and perhaps with the ER
transcriptional program defining each tumor.
The majority of refractory luminal tumors retain ER, but transition from estrogen
dependency to utilize alternate signaling pathways for growth and survival, including PI3K/
AKT/mTOR, EGFR/HER2, AR, and cell cycle regulators such as Cyclin D1 [13–15]. To
date, targeting alternative molecules in resistant tumors has improved outcomes but has
failed to replicate the clinical success of targeting HER2. Thus, there remains a pressing and
unmet clinical need for understanding the process of inherent and acquired endocrine
resistance. A second but not mutually exclusive theory of endocrine resistance posits that
breast tumors contain populations of cancer stem cells that are less susceptible to eradication
with conventional therapies [16]. Most ER+ luminal tumors, however, contain low (<1 %)
levels of cancer stem cells as defined by the two predominant signatures CD44+CD24(−/
low) and aldehyde dehydrogenase (ALDH)+ [17–19]. Many luminal tumors contain cell
subpopulations that express cytokeratin 5 (CK5), a marker of stem and progenitor cells in
the normal breast [20, 21]. These luminal tumor CK56+ cells are ER− PR− and have
increased resistance to endocrine and chemotherapies [22]. The near absence of currently
defined cancer stem cells in many advanced luminal tumors suggests the existence of as yet
undefined luminal-specific cancer stem cells, or that tumor progression is undertaken
stochastically by the bulk ER+ cells themselves.
The molecular mechanisms of ER action have historically been defined in a cohort of ER+
breast cancer cell lines, predominantly ER-rich MCF7 cells, derived from late stage
metastatic disease. These include, among many things, the global ER transcriptome and
cistrome [23–25], and anti-estrogen actions in ER+ solid tumor xenografts [26, 27]. Fresh
tumor samples offer insight into mechanisms of endocrine resistance including changes in
gene expression pre- and post-neoadjuvant endocrine therapy in responsive and non-
responsive tumors [28, 29], and alterations in the ER cistrome in drug resistant ER+ breast
cancers [30]. Individual patient centric models are now needed to address heterogeneity of
response and the development of more personalized therapies. Transplantable in vivo
models of ER+ breast cancers have been historically difficult to develop, and only a few
successes have been described [31, 32]. Loss of ER expression, low take rate, and
preferential engraftment of high grade, rapidly proliferating tumors have contributed to this
difficulty. A recent study describes highly improved establishment of breast cancer grafts,
both TN and ER+, with phenotypic similarities to the original samples [33]. Overall, luminal
tumors remain underrepresented and engraftment still tends to favor the faster growing TN
breast cancers. Herein we describe the development and characterization of five
transplantable luminal ER+ human breast cancers, derived from both primary untreated
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tumors and late stage metastases. These contain various levels of ER (5–99 %), PR, and AR,
and continue to express these steroid receptors for multiple passages at similar levels to the
original tumors. The in vivo estrogen dependency of these tumors is marked and without
change over passages. Profiling of select ER+ tumor grafts with or without estrogen or
endocrine treatments disclosed signaling networks underlying each individual tumor, as well
as a common base ER transcriptome that is also retained in historic ER+ breast cancer cell
line models. These studies highlight the importance of modeling widely diverse patient-
derived ER+ breast cancers in vivo to advance our understanding and treatment of this
disease.
Materials and methods
Tumor transplantation and propagation
Initial transplantation—Tumors or metastases were collected at surgical resection at
University of Colorado Hospital (Aurora, CO). These studies were performed with
institutional review board approval and informed consent of all patients. A trained
pathologist identified normal versus tumor tissue from the surgical specimens and placed
fresh procured tumor tissue into sterile vials on ice for transport. Female NOD/SCID or
NOD/SCID/ILIIrg−/− mice age 4–7 weeks were purchased from Jackson Laboratories. All
animal studies were performed under an IACUC approved protocol. For primary tumors, 5–
10 mm3 pieces were dipped in Matrigel (BD Biosciences) and inserted into the #4 mammary
fat pads of anesthetized recipient mice using a 10 gauge trochar. For pleural effusions or
ascites, cells were collected by centrifugation, incubated for 2–3 min on ice with hemolysis
buffer (BD Biosciences), collected by centrifugation, suspended in Matrigel, and injected
into the #4 mammary fat pads with 27-gauge insulin syringes. A single silastic pellet
containing 17β-estradiol was implanted into animals receiving ER+ tumor specimens, as
determined by clinical pathology. Tumors were palpated weekly for assessment of tumor
take and thereafter measured weekly, where possible, with a digital caliper. Tumor volume
was estimated by the formula lw 2/2.
Tumor propagation—When tumors reached >1 cm, or after 5–6 months, these were
removed from euthanized animals, partitioned into 10-mm3 pieces, and placed into new
recipient animals under various hormone conditions. This was facilitated by insertion of
single silastic pellets containing placebo, 17β-estra-diol, progesterone, medroxyprogesterone
acetate (MPA), or combinations (all from Sigma), at the time of surgery sub-cutaneously in
the upper lumbar region. Pellet preparation was as described previously [34]. For tamoxifen
treatment, animals were given 1-mg tamoxifen dissolved in peanut oil IP 3× weekly for 3
weeks, or vehicle only. For estrogen withdrawal (EWD), estrogen pellets were surgically
removed from animals for the last 3 weeks of the experiment. Tumor volumes were
measured as described above.
Immunohistochemistry and microscopy
Immunohistochemistry (IHC) was as described previously [35]. Antibodies used were as
follows: AR (AR441, 1:500, DAKO), CK5 (XM26, 1:100, Leica), ER (SP1, 1:100, Thermo-
Fisher), HER2/ErbB2 (29D8, 1:2,000, Cell Signaling), Ki67 (MIB-1, 1:1,000, DAKO), and
PR (1294, 1:500, DAKO). Images were captured using an Olympus BH2 microscope
equipped with a Microfire camera and Picture-frame software. Adobe Photoshop CS5 was
used to perform minimal linear adjustments to brightness/contrast and to assemble pictures
into multipanel figures. All IHC staining was evaluated and scored by a pathologist (J.W.).
For ER, PR, and AR, these were calculated as intensity and percent according to clinical
standards. HER2 and Ki67 scores were calculated via Vias Imaging system software
(Ventana).
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Freshly cut pieces (50–100 mg) of each tumor were placed into 0.5 mL Qiazol (Qiagen)
immediately on necropsy and stored at −80 °C. RNA was prepared using Fast-Prep Lysing
Matrix A (MP Biomedicals) followed by miRNeasy (Qiagen) isolation. RNA concentration
was measured using a Nanodrop 2000 (Thermo Scientific), and integrity analyzed using an
Agilent 2100 Bioanalyzer, and the RNA 6000 Nano kit. Expression profiling was performed
using the Gene Atlas System (Fisher). Briefly, amplified and biotinylated sense strand DNA
targets were hybridized to Affymetrix Human Gene 1.1 ST Array Strips representing 28,875
genes. Microarray data were analyzed using Partek Genomics Suite® v6.5 and Ingenuity
Pathways Analysis®. Array data have been deposited in the Gene Expression Omnibus
(GEO) database under accession GSE36075. Additional details on microarray analyses,
including comparison to MCF7 datasets GSE848 and GSE3834 and molecular subtype
analysis, are described in supplementary methods.
Flow cytometry
Processing of tumors into a single-cell suspension and flow cytometry was performed as
described previously [36]. For these studies, cells were incubated for 30 min with antibodies
CD44-Alexafluor647 (Serotec), CD24-Alexafluor488 (Biolegend), and Pacific Blue
conjugated anti-mouse CD45, CD31, and H-2Kd (Biolegend). Dead cells (propidium iodide
(PI)+) and mouse host cells (Pacific Blue+) were excluded from the analysis.
Quantitative PCR (qPCR)
Total RNA was isolated from frozen pieces of PE4 tumors (placebo, estrogen, or estrogen
plus MPA treated) or breast cancer cell lines BT474, MCF7, T47D, and ZR75 using the
Trizol protocol (Invitrogen). cDNA was prepared using the Versa cDNA kit (Fisher
Scientific) following manufacturer protocols. qPCR was performed using primers specific to
total CT45 (5′:CTCTGCCATGTCCAAAGCAA, 3′:AAG
TCATCAATCTGAGAATCCAATTG), PR (5′:TCGAGCT CACAGCGTTTCTA,
3′:CCCGGGACTGGATAAATGT), and β-actin (5′:GATCATTGCTCCTCCTGAGC,
3′:ACT-CCTGCTTGCTGATCCAC) (Fisher Scientific) using AbsoluteBlue SYBR Green
with Fluorescein Mix (Fisher Scientific), 70 nM primers, and 25 ng of the cDNA in 96-well
plates. Standard curves were generated from 2 to 50 ng of standard cDNA (mixed known
cDNAs) run alongside the samples on a Bio-Rad iCycler with MyIQ Single Color Real-
Time PCR Detection System (Bio-Rad). Values were calculated by subtracting the
experimental Ct scores from the untreated Ct scores and controlling for the efficiency of the
reaction, then dividing by the β-actin scores.
Results
Retention of hormone receptor expression in transplantable patient-derived luminal breast
tumor xenografts
Twenty-four samples were implanted into either NOD/ SCID or NOD/SCID/ILIIrg−/− mice
as described. A total of 8/18 ER+ (four metastatic and four primary), and 2/6 TN (both
primary) tumor samples were successfully grafted and propagated beyond passage 1. The
median latency to achieve transplantable tumors (>300 mm3 volume) was 119 days (range
73–228 days). For the purposes of this study, we characterized five ER+ and one TN tumor
sample. Table 1 summarizes the characteristics of the six breast cancers and their
corresponding xenografts. A hemotoxylin and eosin (H&E) stain of each xenograft is
supplied in Supplementary Fig. 1. Tumors were named according to their origin as pleural
effusion (PE), ascites (AS), or primary tumor (PT). Overall, these morphologically
resembled the patient tumor of origin, including grade, ER and PR expression levels, HER2
status, and histological features such as extracellular matrix (mucin) secretion (Table 1;
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Supplementary Fig. 2). To determine if hormone receptors would be retained at similar
levels over multiple passages, sections of each tumor at passage 1 and passages 2–7 were
stained by IHC for ER and PR (Fig. 1). Serially transplanted tumors retained consistent
levels and intensities of ER and PR expression, with some remaining >90 % ER+ PR+ at
passage 7 (PE4). TN PT18 remained ER− PR− for four passages (not shown). HER2 scores
for xenografts (Table 1; Supplementary Fig. 3) matched the clinical diagnosis. AS9 was
HER2 amplified (3+) similar to the cancer of origin and remained 3+ consistently through
passage 3 (Supplementary Fig. 3). AR expression levels were measured by IHC in all six
xenograft tumor lines (Supplementary Fig. 4). Two tumors were 30 % (PT15) and 80 %
(PE4) AR positive, three were AR negative/low (<1 %) (PT12, PT16, PT18), and one had
diffuse cytoplasmic AR staining (AS9). Overall ER+ luminal tumor xenografts resembled
the patient tumor of origin, especially with regard to hormone receptor status, and serve as a
faithful representation of the range of ER levels observed clinically, from low ER (5 %) to
highly ER+ PR+ (>90 %) tumors.
To determine the intrinsic molecular subtype of the patient-derived xenografts, RNA from
first passage tumors (estrogen treated) was profiled on custom Agilent gene expression
microarrays. Each tumor was intrinsically subtyped with PAM50 and claudin-low predictors
to identify luminal A, luminal B, HER2-enriched, basal-like, and claudin-low tumors,
according to previously described methods [37, 38]. Four of the tumors were classified as
luminal B (PE4, AS9, PT12, and PT16), one was HER2-enriched (PT15), and the TN tumor
was basal-like (PT18) (Supplementary Fig. 5). Although PT15 did not overexpress HER2
protein (Table 1; Supplementary Fig. 3), it did express other HER2-associated genes.
Estrogen dependency of ER+ luminal tumor xenografts
To determine hormone responsiveness, tumors were resected from euthanized animals,
partitioned, and placed into new recipient animals supplemented with pellets containing
placebo or estrogen. Tumor growth was measured over time and is plotted in Fig. 2a. Four/
five tumors depended on continuous levels of estrogen for tumor growth, with tumors
growing ~2–20-fold larger in estrogen compared with placebo supplemented animals. In the
case of AS9, no residual tumors could be found in the mammary fat pads of placebo
animals. PT16 was the exception and grew equally well in placebo and estrogen
supplemented animals. This tumor originated from a male patient and thus may be
accustomed to growing under lower estrogen conditions. Note that placebo-treated animals
had intact ovaries and low circulating estrogens [34] but that this was not sufficient for
significant tumor growth in most ER+ samples, that seemingly require continuously
sustained high estrogen levels. TN PT18 tumor xenografts grew robustly without estrogen
supplementation (>1 g tumors by 70 days, not shown). In all cases except for PT16 (p2),
tumors were grown with/without estrogen in subsequent passages with similar results. The
proliferation rates of early passages of each tumor were compared by immunostaining for
Ki67 followed by computerized analysis (Supplementary Table 1). Average Ki67 indices for
luminal ER+ tumors ranged from 36 to 50. TN PT18 had a higher Ki67 score of 68,
comparable to the original tumor score of 65, suggesting the relative rate of tumor cell
proliferation is preserved in these xenograft models.
Because circulating ligand is known to affect receptor turnover, or “downregulation” [39],
we assayed ER expression in tumors without (placebo) or with continuous estrogen
supplementation (Fig. 2b). ER expression was markedly dependent on the hormonal
background of the host animal. In PE4, PT12, and PT15, ER staining (percentages and/or
intensities) was higher in placebo compared with estrogen tumors. PT12 transitioned from
30 to 99 % positive cells in estrogen versus placebo animals. Even PT15 with low ER (1, 5
%) also had a small but consistent and measurable increase in ER (1.5, 8 %) in placebo-
treated animals. PT16 was the exception and had no difference in ER levels without/with
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estrogens, correlating to the observed similarity in tumor growth between the two conditions
(Fig. 2a). There was insignificant material in placebo-treated AS9 animals for analysis,
although ER was already at a maximum (3, 99 %) in estrogen-treated tumors (Fig. 1). These
data suggest that, under continuous estrogens necessary for tumor propagation, ER is often
actively downregulated, and thus the true “resting” ER scores may often be underestimated
in these models.
Endocrine therapy of drug untested ER+ tumors
To determine if primary tumor xenografts obtained from previously untreated patients would
respond to ER-targeted therapies, naive tumors were treated with tamoxifen (PT12 and
PT15) or EWD (PT12) (Fig. 3). For these experiments, tumors were established with
estrogen pellets until they reached 300-mm3 volume, and then randomized into control,
tamoxifen (estrogen pellet retained), and EWD (estrogen pellet removed) groups (PT12
only) for an additional 3 weeks. EWD is surrogate for aromatase inhibitor (AI) therapy,
depleting high circulating estrogens. PT12 tumor volume and final tumor mass did not
change significantly following tamoxifen treatment or EWD, although these trended toward
a decrease, whereas PT15 tumor volume and mass significantly decreased in tamoxifen
compared with estrogen animals (Fig. 3a). The cellularity of PT12 decreased from 70 % in
estrogen-treated tumors to 40 and 20 % in tamoxifen or EWD tumors, respectively (Fig. 3b),
indicating a positive response to treatment not measurable by size alone. ER staining
increased in tamoxifen (80 %) and EWD (99 %) PT12 tumors compared with estrogen alone
(40 %), and in tamoxifen PT15 (30 %) compared with estrogen alone (5 %) (Fig. 3b). This
parallels the reversal of ER downregulation observed in tumor slices transplanted to placebo
animals (Fig. 2b). Ki67 proliferation scores decreased in endocrine-treated PT12 (44
estrogen, 17 estrogen plus tamoxifen, 10.5 EWD), but remained similar in tamoxifen-treated
PT15 tumors (50.7 estrogen, 47.3 estrogen plus tamoxifen) (Supplementary Table 1).
Collectively, these studies demonstrate endocrine therapy of patient grafted tumors show
features consistent with clinical responses, and therefore will provide unique opportunities
to study the early response of untreated ER+ breast cancers to endocrine treatments and
dissect mechanisms of acquired resistance.
Cancer stem cell populations in ER+ tumor xenografts
To determine if xenografted tumors contain currently defined cancer stem cells, we
measured the CD44+CD24 (−/low) population in the five ER+ luminal tumors (under
estrogen supplementation), and TN PT18. Among the luminal tumors, only PE4 (metastatic
disease) contained a significant population of CD44+CD24(−/low) cells (28 %). PT12 and
PT15 had low CD44+CD24(−/low) cells (4 and ~1 %, respectively) and moderately
differentiated tumors AS9 and PT16 xenografts had a virtual absence of CD44+CD24(−/
low) cells (<0.1 %). In contrast, PT18 had a high percent (~75 %) of CD44+CD24(−/low)
cells, typical for TN tumors. Flow analyses were repeated two to three times for each tumor
with consistent results. Where measured, we found no statistically significant differences in
the CD44+CD24(−/low) populations in placebo- versus estrogen-treated animals (PT12 and
PT16) (not shown). Thus, ER-positive tumor xenografts generally contained low
CD44+CD24(−/low), with the exception of PE4, consistent with that described for ER+
primary patient tumors.
Within luminal tumors, CK5 marks populations of ER− PR− cells that express several stem-
like genes including CD44 [36]. We, therefore, determined the relative expression of CK5
by IHC in the six xenograft tumors, all under estrogen conditions except PT18 (Table 1; Fig.
4b). AS9 and PT16 (shown for PT16) were absent for CK5, and PE4 and PT12 (shown for
PT12) had <1 % CK5+ cells. PT15 and TN PT18 both had 30 % CK5+ cells, albeit in
different patterns. PT15 had somewhat evenly dispersed CK5+ cells throughout the tumor,
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whereas PT18 had focal areas of high CK5 expression adjacent to areas with CK5−
chondrocyte-like differentiation, typical for metaplastic tumors. Note that the presence of
CK5 and CD44+ CD24(−/low) populations did not necessarily correlate; PE4 and PT12
contained CD44+CD24(−/low) populations (4 and 26 %) but were virtually absent for CK5
(<0.1 %), whereas PT15 had a significant CK5+ population (30 %) but low CD44+CD24(−/
low) cells (1 %). Thus, under estrogen conditions, some luminal tumors contain cells
expressing cancer stem cell markers, while others are void of either, underscoring a need to
better understand the factors that drive tumor propagation, drug resistance, and long-term
recurrence in ER+ tumors. We speculate that under conditions where estrogens and
progestins are both present, these levels may fluctuate.
ER-dependent signaling networks in patient-derived tumor xenografts
To determine the functional aspect of the transcription factor ER in luminal xenografts, the
gene expression profiles of PE4 (90 % ER+, +/−estrogen) and PT12 (30 % ER+, +/
−estrogen, tamoxifen or EWD) were assessed using Affymetrix human gene ST 1.1 arrays.
Subsequent analyses were performed with Partek software. We also sought to establish if
ER gene regulation in these tumor models has any cross relevance to ER-regulated genes
mapped in traditional ER+ breast cancer cell line models. To do this, we compared the gene
expression profiles in PE4 and PT12 to select publically available datasets previously
reported for the standard ER+ MCF7 human breast cancer cell line, without or with
estrogen, tamoxifen, and EWD treatment [24, 25, 40]. Bioinformatic details are found in
supplementary methods. The majority of estrogen-regulated genes in PE4 and PT12 were
distinct, whereas 36 up- and 35 down-regulated genes were shared between PE4/PT12 (Fig.
5a). Among these, 4 up- and 12 down-regulated genes were shared with MCF7 cells. Each
individual tumor shared as many estrogen-regulated genes with MCF7 cells as they did with
each other, suggesting the ER transcriptome is cell-specific more so than model-specific.
The top 20 estrogen up- and down-regulated genes in PE4 or PT12 are shown by dendogram
in Fig. 5b. Among the highest estrogen-regulated genes in PE4 are six cancer/ testis
antigens, not previously reported to be estrogen regulated in breast cancers. A supervised
hierarchical cluster using the 71 common gene set between PE4/PT12 segregates the
expression patterns by tumor, followed by hormone (placebo vs. estrogen) (Fig. 5c). Genes
that were estrogen regulated in the MCF7 data sets are indicated, and include the highly
estrogen-sensitive GREB1. Many known estrogen-regulated genes were uniquely regulated
in either PE4 (CXCL12) or PT12 (AREG, IGF1R), but not both tumors. Shared estrogen-
regulated genes between PE4/PT12, PE4/MCF7, and PT12/MCF7 are supplied in
(Supplementary Tables 2–4). The signaling networks activated or deactivated by ER in each
tumor were determined by Ingenuity Pathway Analyses (Fig. 5d). Commonalities include
downregulation of the transporter ABCC5 (PE4/PT12 and MCF7), and activation of GREB1
(PE4/MCF7) and IGF1R (PT12/MCF7). However, most affected networks are unique to
each tumor, including activation of enzymes in the mitochondrial respiratory chain in PE4
(UQCRH and UQCRFS1), and activation of additional plasma membrane signaling
molecules in PT12 (GPR125 and CELSR2). The molecule/pathway with the most
significant difference between placebo- and estrogentreated tumors centered on MYC in
PE4, and YWHAG (14-3-3 gamma) in PT12 (Supplementary Fig. 6). These data highlight
the complexity of the ER transcriptome in breast cancers, and that disease-unique, as well as
common factors, may play critical roles in disease progression.
To map changes in estrogen signaling affected by endocrine therapy in PT12, we cross-
compared estrogen-regulated genes that were reversed by both tamoxifen and EWD (Fig. 6a,
b). Overall, EWD abrogated estrogen signaling more robustly than tamoxifen (1,487 vs. 373
total affected genes) (Fig. 6a). The observed difference is possibly because of more
complete blockade of estrogen signaling with EWD compared with direct ligand
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competition for ER with tamoxifen. In addition, tamoxifen acts as a partial agonist on ER
responsive genes [41], contributing to the overall differences in gene expression profiles.
Hierarchical cluster analysis was used to map the genes (46 total) that were estrogen
upregulated and decreased by Tam and EWD (35 genes), or estrogen downregulated and
increased by Tam and EWD (15 genes) (Fig. 6b). Overall, these clustered by estrogen versus
non-estrogen conditions (placebo, tamoxifen, EWD). One tumor was partially resistant to
EWD, and still clustered with the estrogen samples. Twelve/46 common tamoxifen/EWD
sensitive genes were also affected in short term MCF7 tamoxifen and/or EWD models
determined from datasets GSE848 and GSE3834 (marked by asterisks). Four estrogen
upregulated genes (GREB1, IGFR1, NRIP, and PRSS; none downregulated) were abrogated
by both tamoxifen and EWD in PT12 tumors, and in the tamoxifen and EWD MCF7
datasets (Fig. 6d). Indeed, GREB1 and IFG1R are estrogen-regulated across multiple breast
cancer models [42–44]. Ingenuity analysis determined the major networks affected in
tamoxifen- versus EWD-treated PT12. Tamoxifen affected Rb-associated genes (Rb, RBL1,
RBL2) and replication proteins in the mini chromosome maintenance family (MCM2,
MCM6, MCM8, andMCM10), whereas EWD most highly affected molecules involved in
solute transport (SLC4A8 and SLC30A1), the ubiquitin protein ligase complex (COPS7A,
COPS7B, COPS6, and DET1), and DNA damage response (DDB1, DDB2, and DTL) (Fig.
6d). While these molecules were affected in responsive tumors, longer treatment and
resistance studies in these models will determine which pathways eventually drive recurrent
tumors. These data put forward that while some estrogen-regulated genes and signaling
networks (i.e., GREB1 and IGF1R) are apparently broadly conserved among ER+ tumors,
each tumor also has its own unique estrogen-dependent targetable pathways that will need to
be considered for more individualized treatments.
Unique estrogen-regulated genes in tumors
To confirm the estrogen regulation of select genes in tumors, we chose a well-known
estrogen-responsive gene and a group of previously undescribed estrogen-regulated genes
for analysis. The gene for PR, PGR, is well described as estrogen/ER regulated in many
breast tumors, and is used regularly as a marker of functional ER. Cancer/testis antigen
family 45 members A1–6 belong to a group of genes normally expressed only in germ cells,
but are aberrantly expressed in many tumor types, including about 10 % of breast cancers
[45, 46]. By microarray analysis, both PGR and all six CT45 genes (A1–6) were
significantly regulated by estrogen compared with placebo in PE4 (Fig. 7a). PE4 is
indicative of a subset of advanced luminal tumors that respond to treatment with high-dose
synthetic progestins [47]. Estrogen plus progestin (MPA) combination significantly
inhibited the estrogen alone induced growth of PE4 to near placebo controls as measured by
tumor volume and mass (Fig. 7b). Of note is the MPA progestin levels we used can be
extrapolated to be near 20 ng/mL based on measuring serum progesterone give at the same
dose [34], whereas the high doses used in MPA progestin therapy are >150 ng/mL [48]. The
natural hormone progesterone is also effective at blocking estrogen-induced growth of PE4
(not shown), and we therefore conclude that blockade of estrogen signaling occurs at
physiological levels. IHC for PR confirmed its upregulation by estrogen, compared with
placebo, and that addition of MPA abrogates that increase (Fig. 7c). Progestin treatment may
be contributing to PR loss through receptor downregulation, similar to that observed for ER
(Fig. 2). However, PGR mRNA was also significantly decreased in estrogen plus MPA-
treated tumors as measured by qPCR (Fig. 7c). Using a probe that measures all CT45 family
members, qPCR demonstrated that MPA treatment significantly decreased expression of
CT45 in PE4 tumors (Fig. 7d). Additionally, only select luminal breast cancer cell lines
express CT45 (Fig. 7d). T47D cells express the CT45 genes whereas BT474, MCF7, and
ZR75 were absent for CT45 expression. At present, there are no commercially available
CT45 antibodies that are competent for IHC analysis. Cancer/testis antigens are being
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explored as therapeutic targets, because of their antigenicity and virtual absence in normal
adult tissues, and ability to elicit cytotoxic T cell response in cancer vaccines [46]. The
finding that some of these genes are potently estrogen regulated and that their expression is
decreased in regressing tumors suggests they may provide a tumor-unique target in
combination with endocrine therapies in a select set of ER+ breast tumors.
Discussion
Despite many advances in our knowledge of ER+ breast cancer, we are still relatively naive
in our mechanistic understanding of refractory endocrine-resistant disease. One reason is
that this largest group of breast cancers has considerable intra-subtype diversity with
differences in histopathologic features, and expression of other growth factors and receptors,
among genetic and epigenetic factors. It is clear that ER dynamics play a central role in
tumor behavior [49], and it is likely that the ER cistrome/ transcriptomes are divergent in
individual patient samples. While a battery of breast cancer cell lines representing different
subtypes are available for study, we believe that the presented model provides a
complementary approach that has distinct advantages. First, intra-tumoral heterogeneity in
ER expression clearly plays an important role in treatment response—patient-derived tumor
models are more likely to maintain such cellular diversity. Second, translating pre-clinical
findings into clinical successes is likely to be more efficacious from tumor models. The
described tumors maintain stable ER expression levels over multiple passages and will allow
for seamless manipulation and specific study of both ER+ and ER− tumor cell populations.
In some cases, tumors have not been previously drug treated, affording a unique opportunity
to map the nascent ER transcriptome, as well as changes incurred under endocrine therapy
pressure.
Although endocrine therapies remain fundamental to treating ER+ breast cancers, several
alternate signaling molecules have been targeted in these tumors alone or in combination
therapies. HER2-directed therapies have vastly improved treatment outcomes, providing
reason to believe other molecules exist with similar potential [50]. However, HER1/EGFR-
targeted agents, mainly gefitinib, have offered only modest improvement in clinical trials
[51]. Everolimus, an mTOR inhibitor, is the first in a long list of combination therapies to
prove clinically beneficial in a phase III trial [52]. However, even in mTOR responsive
tumors, we inevitably need to narrow down the ideal target patient population. Non-
responsive tumors to targeted therapies likely have different pathways driving tumor
survival. Here, we demonstrate that two ER+ estrogen-dependent breast cancers isolated
from patients and directly propagated in vivo, PE4 and PT12, have predominantly different
ER transcriptomes, although they share a small set of common estrogen-regulated genes.
The most significant pathway active in estrogen-treated PE4 centers on MYC, whereas in
PT12 it centers on YWHAG (14-3-3 gamma) (Supplementary Fig. 6). PE4 originates from a
previously endocrine-treated cancer, that metastasized, and it is therefore likely that its
progression was partially MYC-driven [53]. PT12, a previously untreated, but relatively
rapid growing tumor, seemingly utilizes the highly conserved 14-3-3 gamma protein, a
member of a family of signal transduction modulating molecules potentially involved in
tumor cell survival [54]. EWD effectively reversed 14-3-3 gamma expression while
tamoxifen did not, highlighting important mechanistic differences between the two
predominant endocrine therapies. The partial agonist activity of tamoxifen through ER
compared with the effective absence of liganded ER in EWD presumably led to
differentially affected estrogen responsive pathways. By contrast, four highly estrogen-
dependent genes (GREB1, IGF1R, NRIP1, and PRSS23) were significantly reduced across
cell line (MCF7) and tumor (PT12) models with both therapies (tamoxifen and EWD).
Development of treatment-resistant sublines of these models analogous to those described
for MCF7 tumor xenografts [26, 27] will ultimately determine which escape pathways
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become activated in each tumor. While the number of samples analyzed in these models is
likely to be moderate, they will provide more in depth mechanistic data on each individual
tumor, including the potential to test combination therapies in pre-clinical models. For
example, we show here that a group of X-linked aberrantly expressed cancer/testis antigens
is estrogen-regulated and treatment-sensitive, and therefore could serve as a possible
additional target or marker of response in a subset of luminal breast tumors.
Cancer stem cells offer an intriguing theory for endocrine resistance in ER+ tumors,
especially because they are routinely described as ER− [55, 56], and would thus naturally
avoid anti-ER-targeted therapies. ER+ cell lines and their corresponding xenograft tumors
contain low cancer stem cell populations characterized by either CD44+CD24(−/low) or
CK5+ER−PR− [19, 36], while both of these markers are in much higher abundance in TN
cell lines and tumors [17, 18]. Treatment of ER+ tumors with the aromatase inhibitor
letrozole increased the CD44+CD24(−/low) population [28], and ER+ cells treated with
tamoxifen or EWD have an accumulation of CK5+ cells [22, 57]. Here we confirm that ER+
luminal tumor xenografts generally contain low numbers of CD44+CD24(−/low) and CK5+
cells. PT12 had a small (4 %) CD44+CD24(−/low) population and negligible (<0.1 %)
CK5+ cells, under estrogen conditions. PT15 by contrast contained low (~1 %)
CD44+CD24(−/low) cells (albeit nearly uniformly CD44+CD24 +), but had a relatively high
(~30 %) CK5+ cell population. It is likely that CSC populations will fluctuate under
different hormone conditions as both circulating estradiol and progesterone affect their
numbers [36, 58]. Although we have not fully explored these scenarios in this report,
tamoxifen treatment of PT15 did not lead to a significant increase in the CK5+ cell
population (not shown), although the ER+ cell population notably intensified. Because PR
levels and progesterone are important for the regulation of stem cells in the normal breast
and perhaps some cancers [3], it is likely these will fluctuate under different hormone
conditions. Therefore, while cancer stem cell populations likely contribute to drug resistance
in some ER+ breast cancers, a combination of stem-like cells and a general adaptation of the
bulk ER+ tumor cells may culminate to produce resistant luminal disease. Of note is that
tumors such as AS9 and PT16, a metastatic and grade 3 lesion, have near absent populations
of both CD44+CD24(−/low) and CK5+ cells (<0.1 % each). We speculate that some ER+
tumors have luminal-specific cancer stem cells that are as yet undiscovered, and some
moderate to well-differentiated breast cancers may not fit the current cancer stem cell model
[59].
It is intriguing that molecular subtyping categorized four of the five ER+ tumors as luminal
B and one as having the HER2-enriched gene signature, while none fell into the luminal A
category. Likewise, ER+ tumor grafts were all characterized as luminal B in the DeRose et
al. study [33]. The five luminal xenografts described here displayed a wide variety in ER
expression levels (5–99 %) and moderate to high proliferation rates (Ki67 scores 36–50). It
is possible that the amount of proliferation necessary to produce transplantable tumors in
these mouse models under the experimental time constraint may necessarily lead to a
luminal B phenotype on output. This seems likely as near half of transplanted ER+ tumors
would fall into the luminal A category if subtyped from the original biopsy without further
manipulation [37]. The successful grafting of moderately differentiated and slower growing
tumors (AS9 and PT16) lends optimism for the eventual grafting and maintenance of
luminal A subtype tumors. Nonetheless, the demonstration of functional ER in diverse
individual breast cancers supports the use of this model to dissect ER action and response to
therapy regardless of subtype category.
Patient-derived xenografts will also provide unique opportunities to dissect the contributions
of other steroid hormones and their receptors in breast cancer biology, particularly AR and
PR. Because AR is a tumor suppressor in most ER+ tumors, but a tumor promoter in some
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ER− AR+ tumors [5, 6, 60], grafted tumors with different ER, PR, and AR status will allow
the exploration of AR-specific tumor effects, alone or in the context of each other, under
tightly controlled ligand conditions (estrogens, progestins, and androgens). While PR is a
superb prognostic indicator, and progestins clearly are detrimental in the inception of breast
disease [2, 61], the influence of progestins on established tumors has remained elusive [47].
These models will allow the dissection of PR action in tumors with a wide heterogeneity of
PR expression. The PR transcriptome has been described in relatively few human models
including 3D organoid models of normal breast tissue and PR-rich T47D breast cancer cells
[62, 63]. In addition, the PR cistrome was recently reported for the first time in an
immortalized breast cancer cell line (MCF10A stably expressing PR) and T47D cells [64].
Of note, there was little overlap between normal and cancer models in regard to both PR-
binding sites and PR-regulated genes [63, 64]. We now have the prospect of mapping PR
gene regulation patterns in diverse breast tumor samples with various PR levels.
In summary, patient-derived ER+ tumor xenografts display estrogen-dependent growth and
have unique ER transcriptomes. While multiple other factors such as genetic and epigenetic
signatures, and co-regulator expression patterns, collectively influence tumor behavior, ER
remains the common denominator driving tumor growth and survival, at least initially.
Because ER is retained in most drug-resistant tumors, determining the “switch” in activated/
deactivated genes and signaling networks under treatment pressure in individual tumors is
cornerstone to overcoming persistent ER+ breast disease. This approach will advance the
study of ER and other steroid receptors in individual breast tumors, by allowing relatively
rapid analysis of transcriptome dynamics and therapeutic responses. Clinically, there is a
push toward more individualized medicine. It is conceivable that the pathways involved in
estrogen promotion, and on estrogen deprivation could be discerned in a matter of months—
yielding patient centric tumor data that may ultimately inform treatment options.
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Retention of ER and PR expression in patient-derived luminal breast cancer xenografts over
multiple passages. Patient-derived xenografts were established in NOD/SCID or NOD/
SCID/ILIIrg−/− mice, and subsequently propagated via direct transplantation of solid tumor
pieces into new recipient mice. Tumors were grown under continuous estrogen
supplementation. Sections of five xenograft tumor lines were stained by IHC for ER (left
panels) and PR (right panels) at passage 1, and at subsequent passages 2–7 as indicated. The
intensity (1–3) and percent of ER+ and PR+ cells are indicated on each panel. Scale bars,
100 µM
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Growth kinetics of ER+ breast cancer xenografts in the absence or presence of estrogens.
Tumors were transplanted into recipient mice either in the absence of exogenously added
hormones (placebo), or in the presence of estrogen (17β-estradiol, E). a Tumor volumes
were measured weekly (once attainable) and plotted versus the number of days of incubation
±SEM. Final tumor mass at necropsy ±SEM was plotted for each hormone treatment.
Sample numbers (tumors): PE4 placebo (6), E (8); AS9 placebo (2), E (5); PT12 placebo
(6), E (8); PT15, placebo (4), E (10); PT16 placebo (2), E (4). Tumor volumes at each time
point, and final tumor masses, were compared using Student’ s t test. For tumor volume, *p
< 0.05 E compared to placebo. For final tumor mass, *p < 0.05. b Sections from tumors
grown in mice containing placebo versus estrogen (E) pellets were stained by IHC for ER.
The staining intensity and percent of ER positive cells are indicated on each panel. Scale
bars, 100 µM
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Endocrine therapy response of previously untreated primary tumor xenografts. a Tumors
PT12 and PT15 were grown under estrogen supplementation (E) until they reached 300 mm3
(40–50 days), then treated for 3 weeks with tamoxifen, 0.6 mg/kg IP 3×/ week (E + Tam), or
removal of the estrogen pellet (PT12, estrogen withdrawal, EWD). Arrows indicate the start
of tamoxifen injections and EWD. Tumor volumes are plotted versus number of days of
incubation. Final tumor masses are shown on the right panel. *p < 0.05 PT15 tumor volume
and tumor mass (E + Tam compared with E). b Sections of PT12 and PT15 tumors from
untreated (E), tamoxifen treated (E + Tam), or EWD animals (PT12 only) were stained by
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H&E or IHC for ER. For PT12 H&E, the percent of tumor cellularity is indicated; the
intensity and percent of ER staining is indicated for PT12 and PT15. Scale bars, 100 µM
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Relative abundance of cancer stem cell markers in ER+ tumor xenografts. a Fresh pieces of
tumors (all from estrogen-treated animals except for PT18, no treatment) were processed
into single cell suspensions, and stained with a cocktail of antibodies to exclude murine host
cells, and antibodies to CD44 (AlexaFLuor647) and CD24 (AlexaFLuor488). Dead cells were
excluded by PI. Unstained cells from each tumor were used to set gates. The percent of cells
with the cancer stem cell signature CD449+CD24(−/low) for each tumor is indicated in the
upper left quadrant. b Sections of tumors were stained by IHC for CK5. The percent of cells
stained is indicated on each panel. Scale bars, 100 µM
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Estrogen-regulated genes and signaling networks in luminal tumor xenografts PE4 and
PT12. The gene expression profiles of tumors PE4 and PT12 grown without (placebo) or
with continuous estrogen (E) were determined using Affymetrix human gene 1.1 ST arrays.
An n of 3 tumors were profiled for all groups except for PT12 E, n of 4. A list of estrogen-
regulated genes in MCF7 cells was assembled by performing a union of significantly
changed genes in data sets GSE848 or GSE3834 (supplementary methods). a Venn diagrams
depicting E up- and down-regulated genes in xenografts PE4, PT12, and MCF7 cells (p <
0.05, > 1.5-fold). b The top 20 E up-and down-regulated genes in PE4 or PT12 are depicted
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by hierarchical cluster. Genes that also changed in MCF7 cells in the same direction are
indicated by underlines/asterisks. c Common E up- (36) and down- (35) regulated genes in
PE4 and PT12 graphed by hierarchical cluster. Underlines/asterisks indicate genes that were
also regulated in the same direction in MCF7 cells. d Schematic map of ER-regulated
pathways, based on cellular location, which are activated (red) or deactivated (green) in PE4
or PT12 tumors. Pathways also significantly affected in MCF7 cells are circled
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Gene expression networks in endocrine therapy treated PT12. The gene expression profiles
of tumor PT12 grown with continuous estrogen for 8 weeks (E), plus tamoxifen for the last 3
weeks (E + Tam), or EWD for the last 3 weeks, were determined using Affymetrix human
gene 1.1 ST arrays. An n of 3 tumors were profiled for all groups except for PT12 E, n of 4.
a Venn diagrams comparing estrogen (E) up-regulated genes (compared with placebo) and
tamoxifen (E + Tam) and EWD down-regulated genes (compared with E), and E down-
regulated genes (compared with placebo) and E + Tam and EWD up-regulated genes
(compared with E). b Hierarchical cluster of E up- and down-regulated genes reversed by
both endocrine therapies (Pl placebo, T E+ tamoxifen, W EWD). Genes changed in the same
direction in MCF7 cells with both tamoxifen and EWD are indicated by boxes and either
tamoxifen or EWD are indicated by asterisks. c Normalized expression (log2) plots of four
genes that significantly changed in both tamoxifen and EWD PT12 tumors, and tamoxifen-
treated MCF7 cells (24 h E vs. 24 h E + 4-hydroxy-tamoxifen [GSE848]), and EWD MCF7
tumors (E vs. 48 h EWD [GSE3834]). d Schematic map based on cellular location of the top
significant gene networks altered in tamoxifen (E + Tam) or EWD PT12 tumors
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Estrogen-regulated target genes in PE4. a Relative expression levels of the genes for PR
(PGR) and cancer/testis antigen family 45 (CT45) members A1-6 in placebo versus estrogen
(E) treated PE4 tumors. Expression derived from Affymetrix microarray data analysis, n of 3
each, *p < 0.05 E compared with placebo. b Tumor volume (left) and tumor mass (right)
±SEM of PE4 grown under placebo, estrogen (E), or estrogen plus MPA (E + MPA)
conditions. *p < 0.05, E + MPA tumor volume compared with E, tumor mass E relative to
placebo or E + MPA. c Sections of PE4 tumors treated with placebo, E, or E + MPA were
stained by IHC for PR (left). Intensity and percent of cells stained are indicated. Scale bars,
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100 µM. qPCR for PGR was performed on cDNA prepared from duplicate samples of PE4
tumors treated with placebo, E, or E + MPA. *p < 0.05. d qPCR for CT45 (probes cover all
members) on cDNA prepared from duplicate placebo, E, or E + MPA-treated PE4 tumors
(left) or four luminal breast cancer cell lines (right). Values were normalized to β-actin and
plotted as fold change relative to placebo. *p < 0.05 E compared with placebo or E + MPA
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